Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

August 20, 2019

Conditions
Pulmonary Hypertension
Interventions
DRUG

Remodulin

After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.

DRUG

distilled water

After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT02865733 - Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery | Biotech Hunter | Biotech Hunter